US to shell out $1.2B for supplies of Merck's potential Covid-19 antiviral
Pending positive Phase III results, the US government said early Wednesday that it will pay Merck $1.2 billion for about 1.7 million courses of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
